Buelvas Lab

Research focus

ERC Starting Grant · 2024

Overcoming Monocyte Complexity in Pulmonary Fibrosis Progression from Onset to End-Stage

Progressive pulmonary fibrosis (PF) is a debilitating and incurable disease. Scaring of the lung leads to respiratory failure and 50% of patients die 3-5 years after diagnosis. Our understanding of the pathophysiology of PF is unfortunately limited to established and advanced stages when the extensive lung scaring is irreversible. OMEGA is designed to explore new mechanisms underlying PF progression, from early to advanced disease and propose therapies that timely target the disease, prior to becoming permanent. Two lines of evidence are at the core of OMEGA. First, I was among the first to show that circulating monocytes are strongly linked to PF pathology. Which subtypes are important and…

From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.